How Tirzepatide works
Tirzepatide binds both the GIP and GLP-1 receptors. GLP-1 activity slows gastric emptying and amplifies glucose-dependent insulin release, while the GIP arm improves insulin sensitivity and how adipose tissue handles incoming lipids. Two receptors working together produce a stronger satiety and glycemic signal than a GLP-1 agonist alone at comparable exposure.
Reported benefits
- Sustained appetite suppression and reduced food noise
- Improved fasting glucose and HbA1c trajectory
- Meaningful, steady body-weight reduction
- Better postprandial lipid handling
What the research says
Published trial findings, summarised for education. Figures are group averages from controlled studies and are not a promise of individual results.
SURMOUNT-1 (72 weeks, obesity, n≈2,539)
Mean body-weight reduction of about 15% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg versus 3.1% on placebo; roughly a third of participants on the highest dose lost ≥25% of body weight.
New England Journal of Medicine, 2022
SURPASS programme (type 2 diabetes)
HbA1c reductions of approximately 1.9–2.6 percentage points across doses, outperforming semaglutide 1 mg, degludec and glargine comparators, with most participants reaching HbA1c below 7%.
NEJM / The Lancet, 2021
SURMOUNT-OSA and SURPASS-CVOT
Reported large reductions in obstructive sleep apnoea severity (apnoea–hypopnoea index) and cardiovascular outcomes non-inferior to dulaglutide, supporting effects beyond weight and glucose alone.
NEJM, 2024–2025
Tolerability signal across trials
Adverse events were predominantly gastrointestinal — nausea, diarrhoea, constipation — mostly mild-to-moderate and concentrated during dose escalation; discontinuation for side effects stayed in the single digits.
Pooled trial safety data
Reported side effects
Effects reported in published trials, case reports or post-market surveillance. Individual response varies; this list is educational and not exhaustive.
- Nausea, most often during dose escalation
- Diarrhoea, constipation and abdominal discomfort
- Reduced appetite with risk of under-eating protein
- Injection-site reactions and fatigue
Serious or rare signals
- Pancreatitis and gallbladder disease (rare)
- Boxed warning for thyroid C-cell tumours in rodents
- Hypoglycaemia when combined with insulin or sulfonylureas
Regulatory status & sources
Approved by the FDA as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023).
Safety note
Tirzepatide is presented here for research and educational purposes only. It is not offered for human consumption and nothing on this page is medical advice or a dosing protocol. Read the full safety and disclaimer page.